Guggenheim analyst Yatin Suneja raised the firm’s price target on AnaptysBio (ANAB) to $54 from $52 and keeps a Buy rating on the shares. Following Q1 earnings, the firm says it is “encouraged by the company’s clinical development and its robust pipeline.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Hold Rating for AnaptysBio Amid Uncertainties in Clinical Trial Data and Market Position
- AnaptysBio reports Q1 EPS ($1.28), consensus ($1.46)
- Promising Financial Future for AnaptysBio: Buy Rating Justified by Strategic Collaborations and Market Performance
- AnaptysBio could have positive read from J&J abstracts, says Guggenheim
- AnaptysBio board authorizes $75M stock repurchase plan
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue